emendrix

Annex VI

Classification, Labelling and Packaging Regulation · 32008R1272 · every event for this act · on EUR-Lex

Harmonised classification and labelling for certain hazardous substances

26 changes recorded across 26 events, newest first.

in force 2026-05-01 MODIFIED+13,572 −5,286

Amended by Regulation (EU) 2024/2564 32024R2564

applies from: unchanged

Sources disagree — the text comparison found this change; the EU's own amendment metadata does not list it and the amending act's instructions do not mention it. All are shown; none is overruled.

The entry for trimethyl borate (index 005-005-00-1) has been changed so that, in addition to the flammable liquid classification, it now carries a Repr. 1B classification with hazard statement H360FD, alongside a revised Acute Tox. 4 entry, and its pictograms, labelling codes and hazard statements have been updated accordingly, with a Note 11 reference added.

In the earlier version this same entry showed only the flammable liquid and Acute Tox. 4 classifications with hazard statements H226 and H312, without any reproductive toxicity classification or Note 11 reference.

The remainder of the visible Annex VI text, including the introductory parts and the surrounding table entries, is unchanged between the two versions, and the material beyond the truncation marker in both texts is not part of what can be described here.

Cited: Annex VI, v2 · Annex VI, v1

text before / after

02008R1272-20250901 → 02008R1272-20260501

compared line by line: this provision is too large to compare word by word, so a marked line is a line that changed somewhere

ANNEX VI Harmonised classification and labelling for certain hazardous substances Part 1 of this Annex provides an introduction to the list of harmonised classification and labelling, including information listed for each entry and related classifications and hazard statements in Table 3. … 466 unchanged lines … Dgr H250 H314 A 005-005-00-1 trimethyl borate 204-468-9 121-43-7 Flam. Liq. 3 Acute Tox. 4 * H226 Repr. 1B Acute Tox. 4* H226 H360FD H312 GHS02 GHS08 GHS07 Wng H226 H312 005-006-00-7 dibutyltin hydrogen borate 401-040-5 75113-37-0 Repr. 1B Dgr H226 H360FD H312 11 005-006-00-7 dibutyltin hydrogen borate 401-040-5 75113-37-0 Repr. 1B Muta. 2 STOT RE 1 Acute Tox. 4 * … 250 unchanged lines … disodium octaborate tetrahydrate [2] 234-541-0 [1] 234-541-0 [2] 12008-41-2 [1] 12280-03-4 [2] Repr. 1B H360FD GHS08 Dgr H360FD 006-001-00-2 carbon monoxide 211-128-3 630-08-0 Flam. Gas 1 Dgr H360FD 005-023-00-X perboric acid (H3BO2(O2)), monosodium salt trihydrate [1] perboric acid, sodium salt, tetrahydrate [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate [3] sodium peroxoborate, hexahydrate [4] 239-172-9 [1] 234-390-0 [2] - [3] - [4] 13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3] - [4] Repr. 1B Acute Tox. 4 STOT SE 3 Eye Dam. 1 H360FD H332 H335 H318 GHS08 GHS05 GHS07 Dgr H360FD H332 H335 H318 inhalation: ATE = 1,2 mg/L (dusts or mists) Eye Dam. 1; H318: C ≥ 36 % Eye Irrit. 2; H319: 22 % ≤ C < 36 % 11 005-024-00-5 sodium peroxometaborate 231-556-4 7632-04-4 Ox. Sol. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 STOT SE 3 Eye Dam. 1 H272 H360FD H331 H302 H335 H318 GHS03 GHS08 GHS06 GHS05 Dgr H272 H360FD H331 H302 H335 H318 inhalation: ATE = 0,62 mg/L (dusts or mists) oral: ATE = 730 mg/kg bw Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % 11 006-001-00-2 carbon monoxide 211-128-3 630-08-0 Flam. Gas 1 Press. Gas Repr. 1A Acute Tox. 3 * … 1,076 unchanged lines … GHS09 Dgr H318 H334 H410 M=100 007-001-00-5 ammonia, anhydrous 231-635-3 7664-41-7 Flam. Gas 2 H410 M=100 006-104-00-2 multi-walled carbon tubes (synthetic graphite in tubular shape) with a geometric tube diameter range ≥ 30 nm to < 3 μm and a length ≥ 5 μm and aspect ratio > 3:1, including multi-walled carbon nanotubes, MWC(N)T — — Carc. 1B STOT RE 1 H350i H372 (lung)(inhalation) GHS08 Dgr H350i H372 (lung)(inhalation) STOT RE 1; H372: C ≥ 1 %; STOT RE 2; H373: 0,1 % ≤ C < 1 % 007-001-00-5 ammonia, anhydrous 231-635-3 7664-41-7 Flam. Gas 2 Press. Gas Acute Tox. 3 * Skin Corr. 1B … 2,978 unchanged lines … H331 H410 U 016-022-00-9 ethanethiol; ethyl mercaptan 200-837-3 75-08-1 Flam. Liq. 2 Acute Tox. 4 * ethyl mercaptan 200-837-3 75-08-1 Flam. Liq. 1 Acute Tox. 3 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H225 H332 Aquatic Chronic 1 H224 H331 H302 H400 H410 GHS02 GHS07 GHS06 GHS09 Dgr H225 H332 H410 016-023-00-4 dimethyl sulphate 201-058-1 77-78-1 Carc. 1B Dgr H224 H331 H302 H410 inhalation: ATE = 7,1 mg/L (vapours) oral: ATE = 680 mg/kg bw 016-023-00-4 dimethyl sulphate 201-058-1 77-78-1 Carc. 1B Muta. 2 Acute Tox. 2 * Acute Tox. 3 * … 2,808 unchanged lines … Wng H302 H410 oral: ATE = 500 mg/kg bw M = 10 M = 10 029-019-01-X copper flakes (coated with aliphatic acid) — — Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H331 M = 10 029-019-01-X copper flakes (coated with aliphatic acid) Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H331 H302 H319 H400 H410 GHS06 GHS09 Dgr H331 H302 H319 H410 inhalation: ATE = 0,733 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw H410 inhalation: ATE = 0,733 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 10 M = 10 029-020-00-8 copper(II) carbonate—copper(II) hydroxide (1:1) 235-113-6 12069-69-1 Acute Tox. 4 M = 1 029-020-00-8 copper(II) carbonate—copper(II) hydroxide (1:1) 235-113-6 12069-69-1 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 … 79 unchanged lines … H318 H410 oral: ATE = 360 mg/kg bw M = 1 M = 1 030-001-00-1 zinc powder — zinc dust (pyrophoric) 231-175-3 7440-66-6 Water-react. 1 M = 1 029-026-00-0 copper [specific surface area > 0,67 mm2/mg] 231-159-6 7440-50-8 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 10 M = 1 030-001-00-1 zinc powder — zinc dust (pyrophoric) 231-175-3 7440-66-6 Water-react. 1 Pyr. Sol. 1 Aquatic Acute 1 Aquatic Chronic 1 H260 … 386 unchanged lines … H315 H318 H410 M = 100 M = 100 048-001-00-5 cadmium compounds, with the exception of cadmium sulphoselenide (xCdS.yCdSe), reaction mass of cadmium sulphide with zinc sulphide (xCdS.yZnS), reaction mass of cadmium sulphide with mercury sulphide (xCdS.yHgS), and those specified elsewhere in this Annex — — Acute Tox. 4 * M = 100 047-004-00-9 silver massive: [particle diameter ≥ 1 mm] 231-131-3 7440-22-4 Repr. 2 STOT RE 2 H361f H373 (nervous system) GHS08 Wng H361f H373 (nervous system) 047-005-00-4 silver powder: [particle diameter > 100 nm < 1 mm] 231-131-3 7440-22-4 Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H361f H373 (nervous system) H400 H410 GHS08 GHS09 Wng H361f H373 (nervous system) H410 M = 10 M = 10 047-006-00-X silver nano: [particle diameter > 1 nm ≤ 100 nm] 231-131-3 7440-22-4 Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H361f H373 (nervous system) H400 H410 GHS08 GHS09 Wng H361f H373 (nervous system) H410 M = 1000 M = 1000 048-001-00-5 cadmium compounds, with the exception of cadmium sulphoselenide (xCdS.yCdSe), reaction mass of cadmium sulphide with zinc sulphide (xCdS.yZnS), reaction mass of cadmium sulphide with mercury sulphide (xCdS.yHgS), and those specified elsewhere in this Annex — — Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 … 2,125 unchanged lines … H410 601-037-00-0 n-hexane 203-777-6 110-54-3 Flam. Liq. 2 Repr. 2 Asp. Tox. 1 STOT RE 2 * STOT SE 3 STOT RE 1 Skin Irrit. 2 STOT SE 3 Aquatic Chronic 2 H225 H361f *** H304 H373 ** H361f*** H304 H336 H372 (nervous system) H315 H336 H411 GHS02 GHS08 GHS07 GHS09 Dgr H225 H361f *** H304 H373 ** H315 H361f*** H304 H336 H411 STOT RE 2; H373: C ≥ 5 % 601-041-00-2 dibenz[a,h]anthracene 200-181-8 53-70-3 Carc. 1B H372 (nervous system) H315 H411 601-041-00-2 dibenz[a,h]anthracene 200-181-8 53-70-3 Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 H350 H400 … 3,592 unchanged lines … H410 GHS08 GHS09 Wng H373 (teeth, bones) H410 M = 1 604-001-00-2 phenol; carbolic acid; monohydroxybenzene; phenylalcohol 203-632-7 108-95-2 Muta. 2 H410 M = 1 603-247-00-8 reaction mass of 1,3-dioxan-5-ol and 1,3-dioxolan-4-ylmethanol — — Repr. 1B H360Df GHS08 Dgr H360Df 604-001-00-2 phenol; carbolic acid; monohydroxybenzene; phenylalcohol 203-632-7 108-95-2 Muta. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Skin Corr. 1B H341 … 304 unchanged lines … GHS09 Wng H302 H319 H410 604-020-00-6 2-phenylphenol (ISO)biphenyl-2-ol; 2-hydroxybiphenyl; 201-993-5 90-43-7 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 H319 H335 H315 H400 GHS07 H410 604-020-00-6 biphenyl-2-ol; 2-phenylphenol; 2-hydroxybiphenyl 201-993-5 90-43-7 Carc. 2 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 H351 H314 H318 H317 H400 H410 GHS08 GHS05 GHS07 GHS09 Wng H319 H335 H315 H400 604-021-00-1 sodium 2-biphenylate; 2-phenylphenol, sodium salt 205-055-6 132-27-4 Acute Tox. 4 * STOT SE 3 Dgr H351 H314 H317 H410 M = 1 M = 1 604-021-00-1 sodium 2-biphenylate; 2-phenylphenol, sodium salt 205-055-6 132-27-4 Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 H302 … 541 unchanged lines … Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1 M = 10 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. 1B Muta. 2 Acute Tox. 3* Acute Tox. 3* Acute Tox. 3* M = 10 605-001-00-5 formaldehyde … % 200-001-8 50-00-0 Carc. 1B Muta. 2 Acute Tox. 2 Acute Tox. 4 Skin Corr. 1B Skin Sens. 1 H350 Skin Sens. 1A H350 H341 H301 H311 H331 H330 H302 H314 H317 GHS08 GHS06 GHS05 Dgr H350 H341 H301 H311 H331 H330 H302 H314 H317 * Skin Corr. 1B; H314: C ≥25 % Skin Irrit. 2; H315: 5 % ≤C < 25 % Eye Irrit. 2; H319: 5 % ≤ C <25 % STOT SE 3; H335: C ≥ 5 % SkinSens.; H317: C ≥ 0,2 % B, D H317 EUH071 inhalation: ATE = 100 ppmV (gases) oral: ATE = 500 mg/kg bw STOT SE 3; H335: C ≥ 5 % Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 5 % ≤ C < 25 % Eye Irrit. 2; H319: 5 % ≤ C < 25 % B, D, F 605-002-00-0 1,3,5-trioxan; trioxymethylene 203-812-5 110-88-3 Flam. Sol. 1 Repr. 2 STOT SE 3 H228 … 310 unchanged lines … 31906-04-4 [2] 51414-25-6 [3] Skin Sens. 1A H317 GHS07 Wng H317 605-041-00-3 2-(4-tert-butylbenzyl)propionaldehyde 201-289-8 80-54-6 Repr. 1B H360Fd GHS08 Dgr H360Fd 606-001-00-8 acetone; propan-2-one; propanone 200-662-2 67-64-1 Flam. Liq. 2 Dgr H360Fd 605-042-00-9 α-methyl-1,3-benzodioxole-5-propionaldehyde [1] (S)-α-methyl-1,3-benzodioxole-5-propionaldehyde; (2S)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [2] (R)-α-methyl-1,3-benzodioxole-5-propionaldehyde; (2R)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [3] 214-881-6 [1] - [2] - [3] 1205-17-0 [1] 737776-68-0 [2] 737776-59-9 [3] Skin Sens. 1B H317 GHS07 Wng H317 605-043-00-4 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [1] (1α,2α,5α)-2,5-dimethylcyclohex-3-ene-1-carbaldehyde [2] 2,6-dimethylcyclohex-3-ene-1-carbaldehyde [3] 3,5-dimethylcyclohex-3-ene-1-carbaldehyde [4] 3,6-dimethylcyclohex-3-ene-1-carbaldehyde [5] 4,6-dimethylcyclohex-3-ene-1-carbaldehyde [6] reaction mass of 3,5-dimethylcyclohex-3-ene-1-carbaldehyde and 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [7] dimethylcyclohex-3-ene-1-carbaldehyde [8] Dimethylcyclohex-3-ene-1-carbaldehyde [9] 1,2,4(or 1,3,5)-trimethylcyclohex-3-ene-1-carbaldehyde [10] 1,3,4-trimethylcyclohex-3-ene-1-carbaldehyde [11] 2,2,4-trimethylcyclohex-3-ene-1-carbaldehyde [12] 2,4,6-trimethylcyclohex-3-enecarbaldehyde [13] isocyclocitral [14] 3,5,6-trimethylcyclohex-3-ene-1-carbaldehyde [15] 4,6,6-trimethylcyclohex-3-ene-1-carbaldehyde [16] 268-264-1 [1] 252-395-6 [2] - [3] 268-263-6 [4] 267-186-5 [5] 253-139-6 [6] - [7] 248-742-6 [8] 272-113-5 [9] 276-055-1 [10] - [11] - [12] 215-833-7 [13] 215-638-7 [14] 266-810-3 [15] - [16] 68039-49-6 [1] 35145-02-9 [2] 6975-94-6 [3] 68039-48-5 [4] 67801-65-4 [5] 36635-35-5 [6] - [7] 27939-60-2 [8] 68737-61-1 [9] 71832-78-5 [10] 40702-26-9 [11] 1726-47-2 [12] 1423-46-7 [13] 1335-66-6 [14] 67634-07-5 [15] 6754-27-4 [16] Skin Sens. 1 H317 GHS07 Wng H317 606-001-00-8 acetone; propan-2-one; propanone 200-662-2 67-64-1 Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 H225 H319 … 870 unchanged lines … M = 10 606-155-00-6 cinnamaldehyde; 3-phenylprop-2-enal; cinnamic aldehyde; cinnamal; [1] (2E)-3-phenylprop-2-enal [2] 203-213-9 [1] - [2] 104-55-2 [1] 14371-10-9 [2] Skin Sens. 1A H317 GHS07 Wng H317 Skin Sens. 1A; H317: C ≥ 0,01 % 607-001-00-0 formic acid … % 200-579-1 64-18-6 Skin Corr. 1A H314 GHS05 Dgr H314 Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; H314: 10 % ≤ C < 90 % Skin Irrit. 2; H315: 2 % ≤C < 10 % Eye Irrit. 2; H319: 2 %≤ <10 % B Wng H317 Skin Sens. 1A; H317: C ≥ 0,01 % 606-157-00-7 (3E)-dec-3-en-2-one — 18402-84-1 Acute Tox. 4 Asp. Tox. 1 Skin Irrit. 2 Aquatic Chronic 2 H332 H304 H315 H411 GHS07 GHS08 GHS09 Dgr H332 H304 H315 H411 EUH071 inhalation: ATE = 1,5 mg/L (dusts or mists) 606-158-00-2 2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one 438-340-0 119344-86-4 Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 H360Df H400 H410 GHS08 GHS09 Dgr H360Df H410 M = 1 M = 1 607-001-00-0 formic acid … % 200-579-1 64-18-6 Flam. Liq. 3 Met. Corr. 1 Acute Tox. 3 Acute Tox. 4 Skin Corr. 1A Eye Dam. 1 H226 H290 H331 H302 H314 H318 GHS02 GHS05 GHS06 Dgr H226 H290 H331 H302 H314 EUH071 inhalation: ATE = 7,4 mg/L (vapours) oral: ATE = 500 mg/kg bw Flam. Liq. 3; H226: C > 85 % Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; 314: 10 % ≤ C < 90 % Skin Irrit. 2; H315: 2 % ≤ C < 10 % Eye Dam. 1; H318: C ≥ 10 % Eye Irrit. 2; H319: 2 % ≤ C < 10 % B 607-002-00-6 acetic acid … % 200-580-7 64-19-7 Flam. Liq. 3 Skin Corr. 1A H226 H314 GHS02 … 412 unchanged lines … H335 H315 H410 A 607-043-00-X dicamba (ISO); 2,5-dichloro-6-methoxybenzoic acid; 3,6-dichloro-2-methoxybenzoic acid 217-635-6 1918-00-9 Acute Tox. 4 * 607-043-00-X dicamba (ISO); 2,5-dichloro-6-methoxybenzoic acid; 3,6-dichloro-2-methoxybenzoic acid 217-635-6 1918-00-9 Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT SE 3 Eye Dam. 1 Aquatic Chronic 3 H302 Aquatic Acute 1 Aquatic Chronic 2 H332 H302 H335 H336 H318 H412 GHS05 GHS07 Dgr H302 H400 H411 GHS07 GHS05 GHS09 Dgr H332 H302 H335 H336 H318 H412 607-044-00-5 3,6-dichloro-o-anisic acid, compound with dimethylamine (1:1); [1] potassium 3,6-dichloro-o-anisate[2] 218-951-7 [1] H410 inhalation: ATE = 4,0 mg/L (dusts or mists) oral: ATE = 1500 mg/kg bw M = 1 607-044-00-5 3,6-dichloro-o-anisic acid, compound with dimethylamine (1:1); [1] potassium 3,6-dichloro-o-anisate[2] 218-951-7 [1] 233-002-7 [2] 2300-66-5 [1] 10007-85-9 [2] Eye Irrit. 2 Aquatic Chronic 3 H319 … 442 unchanged lines … GHS05 Dgr H225 H314 EUH014 B D 607-094-00-8 peracetic acid . . . % 201-186-8 79-21-0 Flam. Liq. 3 Org. Perox. D **** Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A Aquatic Acute 1 H226 H242 H332 H312 H302 607-094-00-8 peracetic acid … % 201-186-8 79-21-0 Org. Perox. D Acute Tox. 2 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1A Aquatic Acute 1 Aquatic Chronic 1 H242 H330 H310 H301 H314 H400 GHS02 H400 H410 GHS02 GHS06 GHS05 GHS07 GHS09 Dgr H226 H242 H332 H312 H302 Dgr H242 H330 H310 H301 H314 H400 * STOT SE 3; H335: C ≥ 1 % B D H410 EUH071 inhalation: ATE = 0,2 mg/L (dusts or mists) dermal: ATE = 60 mg/kg bw oral: ATE = 80 mg/kg bw STOT SE 3; H335: C ≥ 1 % M = 10 M = 100 B, D, T 607-095-00-3 maleic acid 203-742-5 110-16-7 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 … 811 unchanged lines … H412 GHS07 Wng H315 H319 H412 607-198-00-3 propyl 3,4,5-trihydroxybenzoate 204-498-2 121-79-9 Acute Tox. 4 * Skin Sens. 1 H302 H317 GHS07 H412 607-198-00-3 propyl 3,4,5-trihydroxybenzoate 204-498-2 121-79-9 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H302 H317 H400 H410 GHS07 GHS09 Wng H302 H317 607-199-00-9 octyl 3,4,5-trihydroxybenzoate 213-853-0 1034-01-1 Acute Tox. 4 * H317 H410 oral: ATE = 1700 mg/kg bw M = 1 M = 1 607-199-00-9 octyl 3,4,5-trihydroxybenzoate 213-853-0 1034-01-1 Acute Tox. 4 * Skin Sens. 1 H302 H317 GHS07 Wng H302 … 1,428 unchanged lines … GHS09 Dgr H331 H302 H410 607-432-00-4 S-metolachlor; reaction mass of (S)-2-chloro-N-(2-ethyl-6-methyl-phenyl)-N-(2-methoxy-1-methyl-ethyl)-acetamide (80-100 %); [1] (R)-2-chloro-N-(2-ethyl-6-methyl-phenyl)-N-(2-methoxy-1-methyl-ethyl)-acetamide (0-20 %) [2] -[1] -[2] 87392-12-9 [1] 178961-20-1 [2] Skin Sens. 1 H410 607-432-00-4 S-metolachlor (ISO); 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide; (RaSa)-2-chloro-N-(6-ethyl-o-tolyl)-N-[(1S)-2-methoxy-1-methylethyl]acetamide [contains 80-100 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide and 0-20 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2R)-1-methoxypropan-2-yl]acetamide] — 87392-12-9 Carc. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 Aquatic Chronic 1 H351 H317 H400 H410 GHS07 H410 GHS08 GHS07 GHS09 Wng H317 H410 607-433-00-X cypermethrin cis/trans +/-80/20; (RS)-α-cyano-3-phenoxybenzyl (1RS;3RS; 1RS, 3SR)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate 257-842-9 52315-07-8 Acute Tox. 4 * STOT SE 3 Wng H351 H317 H410 EUH066 M = 10 M = 10 607-433-00-X cypermethrin cis/trans +/-80/20; (RS)-α-cyano-3-phenoxybenzyl (1RS;3RS; 1RS, 3SR)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate 257-842-9 52315-07-8 Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 … 1,739 unchanged lines … H410 oral: ATE = 1500 mg/kg bw M = 1000 M = 1000 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2 M = 1000 607-770-00-2 2,3-epoxypropyl neodecanoate 247-979-2 26761-45-5 Muta. 2 Skin Sens. 1A H341 H317 GHS08 GHS07 Wng H341 H317 Skin Sens. 1A; H317: C ≥ 0,001 % 607-771-00-8 benthiavalicarb-isopropyl (ISO); isopropyl [(S)-1-{[(R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]carbamoyl}-2-methylpropyl]carbamate — 177406-68-7 Carc. 1B Repr. 2 Skin Sens. 1 Aquatic Chronic 2 H350 H361fd H317 H411 GHS08 GHS07 GHS09 Dgr H350 H361fd H317 H411 607-772-00-3 hexyl salicylate 228-408-6 6259-76-3 Repr. 2 Skin Sens. 1 H361d H317 GHS08 GHS07 Wng H361d H317 607-773-00-9 7-oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate 219-207-4 2386-87-0 Muta. 2 STOT RE 2 Skin Sens. 1 H341 H373 (nasal cavity) H317 GHS08 GHS07 Wng H341 H373 (nasal cavity) H317 607-774-00-4 tetrasodium 4-amino-5-hydroxy-3,6-bis[[4-[[2-(sulphonatooxy)ethyl]sulphonyl]phenyl]azo]naphthalene-2,7-disulphonate [1] Reaction products of 4-amino-5-hydroxynaphthalene-2,7-disulfonic acid, coupled twice with diazotized 2-[(4-aminophenyl)sulfonyl]ethyl hydrogen sulfate, sodium salts [2] disodium 4-amino-5-hydroxy-3,6-bis{[4-(vinylsulfonyl) phenyl]diazenyl}naphthalene-2,7-disulfonate [3] 241-164-5 [1] - [2] - [3] 17095-24-8 [1] - [2] 100556-82-9 [3] Resp. Sens. 1A Skin Sens. 1 H334 H317 GHS08 Dgr H334 H317 607-775-00-X Sodium 3-(allyloxy)-2-hydroxypropanesulphonate 258-004-5 52556-42-0 Repr. 1B Eye Dam. 1 H360F H318 GHS08 GHS05 Dgr H360F H318 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 H225 H332 … 1,535 unchanged lines … H302 H317 H412 609-073-00-9 lithium potassium sodium N,N''-bis{6-[7-[4-(4-chloro-1,3,5-triazin-2-yl)amino-4-(2-ureidophenylazo)]naphthalene-1,3,6-trisulfonato}-N'-(2-aminoethyl)piperazine 427-850-9 — Skin Sens. 1 H317 GHS07 Wng H317 610-001-00-3 trichloronitromethane; Wng H317 609-074-00-4 1,4-dichloro-2-nitrobenzene 201-923-3 89-61-2 Carc. 1B H350 GHS08 Dgr H350 610-001-00-3 trichloronitromethane; chloropicrin 200-930-9 76-06-2 Acute Tox. 2 * Acute Tox. 4 * Eye Irrit. 2 … 1,021 unchanged lines … H373 (liver) H315 H318 H411 oral: ATE = 136 mg/kg bw 612-001-00-9 mono-methylamine; [1] H411 oral: ATE = 136 mg/kg bw 611-182-00-1 2-[ethyl[3-methyl-4-[(5-nitrothiazol-2-yl)azo]phenyl]amino]ethanol 271-183-4 68516-81-4 Skin Sens. 1A H317 GHS07 Wng H317 Skin Sens. 1A; H317: C ≥ 0,001 % 612-001-00-9 mono-methylamine; [1] di-methylamine; [2] tri-methylamine [3] 200-820-0 [1] 204-697-4 [2] … 3,599 unchanged lines … H317 GHS08 GHS07 Dgr H360FD H317 613-001-00-1 ethyleneimine; aziridine 205-793-9 151-56-4 Flam. Liq. 2 H317 612-299-00-0 fenpropidin (ISO); (R,S)-1-[3-(4-tert-butylphenyl)-2-methylpropyl]piperidine — 67306-00-7 Repr. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT SE 3 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H361d H332 H302 H335 H336 H373 (nervous system, eyes, lungs) H315 H318 H317 H400 H410 GHS08 GHS07 GHS05 GHS09 Dgr H361d H332 H302 H335 H336 H373 (nervous system, eyes, lungs) H315 H318 H317 H410 Inhalation: ATE = 1,2 mg/L (dusts or mists) oral: ATE = 1330 mg/kg bw M = 1000 M = 10000 613-001-00-1 ethyleneimine; aziridine 205-793-9 151-56-4 Flam. Liq. 2 Carc. 1B Muta. 1B Acute Tox. 2 * … 2,219 unchanged lines … H410 GHS07 GHS09 Wng H317 H410 M=10 613-272-00-6 pyraclostrobin (ISO); methyl N-{2-[1-(4-chlorophenyl)-1H-pyrazol-3-yloxymethyl]phenyl}(N-methoxy)carbamate — — Acute Tox. 3 * H410 M=10 613-272-00-6 pyraclostrobin (ISO); methyl N-(2-{[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxymethyl}phenyl) N-methoxy carbamate — 175013-18-0 Repr. 2 Acute Tox. 3 Acute Tox. 4 STOT SE 3 STOT RE 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H331 Aquatic Chronic 1 H361d H331 H302 H335 H373 (liver, gastrointestinal tract, nasal cavity) H315 H400 H410 GHS06 H410 GHS08 GHS06 GHS09 Dgr H331 Dgr H361d H331 H302 H335 H373 (liver, gastrointestinal tract, nasal cavity) H315 H410 M=100 613-273-00-1 tetrahydro-3-methyl-5-((2-phenylthio)thiazol-5-ylmethyl)-[4H]-1,3,5-oxadiazinan-4-ylidene-N-nitroamine 427-600-9 192439-46-6 Aquatic Chronic 2 H411 GHS09 H411 613-274-00-7 2,6-dichloro-1-fluoropyridiniumtetrafluoroborate 427-400-1 140623-89-8 Skin Corr. 1B H410 inhalation: ATE = 0,58 mg/L (dusts or mists) oral: ATE = 450 mg/kg bw M = 100 M = 100 613-273-00-1 tetrahydro-3-methyl-5-((2-phenylthio)thiazol-5-ylmethyl)-[4H]-1,3,5-oxadiazinan-4-ylidene-N-nitroamine 427-600-9 192439-46-6 Aquatic Chronic 2 H411 GHS09 H411 613-274-00-7 2,6-dichloro-1-fluoropyridiniumtetrafluoroborate 427-400-1 140623-89-8 Skin Corr. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 … 732 unchanged lines … Repr. 1B H350 H360Fd GHS08 Dgr H350 H360Fd 614-001-00-4 nicotine (ISO); H360Fd 613-350-00-X 1H-benzotriazole 202-394-1 95-14-7 Aquatic Chronic 2 H411 GHS09 Wng H411 613-351-00-5 methyl-1H-benzotriazole 249-596-6 29385-43-1 Aquatic Chronic 2 H411 GHS09 Wng H411 614-001-00-4 nicotine (ISO); 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine 200-193-3 54-11-5 Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 … 1,503 unchanged lines … GHS07 Wng H302 H373** H412 616-127-00-5 reaction mass of: N, N'-Ethane-1,2-diylbis(decanamide); 12-Hydroxy-N-[2-[1-oxydecyl)amino]ethyl]octadecanamide; N, N'-Ethane-1,2-diylbis(12hydroxyoctadecanamide) 430-050-2 — Skin Sens. 1 Aquatic Chronic 2 H317 H411 GHS07 H412 616-127-00-5 reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide and N,N'-ethane-1,2-diylbis(12-hydroxyoctadecanamide) [1] reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide [2] 430-050-2 [1] - [2] - [1] - [2] Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H411 616-128-00-0 N-(2-(1-allyl-4,5-dicyanoimidazol-2-ylazo)-5-(dipropylamino)phenyl)-acetamide 417-530-7 123590-00-1 Aquatic Chronic 4 H413 — H413 616-129-00-6 N,N'-bis(2,2,6,6-tetramethyl-4-piperidyl)isophthalamide 419-710-0 42774-15-2 Acute Tox. 4 * H410 M = 100 M = 10 616-128-00-0 N-(2-(1-allyl-4,5-dicyanoimidazol-2-ylazo)-5-(dipropylamino)phenyl)-acetamide 417-530-7 123590-00-1 Aquatic Chronic 4 H413 — H413 616-129-00-6 N,N'-bis(2,2,6,6-tetramethyl-4-piperidyl)isophthalamide 419-710-0 42774-15-2 Acute Tox. 4 * Eye Irrit. 2 H302 H319 GHS07 Wng H302 … 590 unchanged lines … GHS09 Wng H373 (blood system, thyroid) H410 M = 1000 M = 1000 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242 M = 1000 616-243-00-6 N,N'-methylenediacrylamide 203-750-9 110-26-9 Muta. 1B H340 GHS08 Dgr H340 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242 H225 H341 GHS02 GHS08 … 70 unchanged lines … GHS09 Wng H242 H315 H411 617-008-00-0 dibenzoyl peroxide; benzoyl peroxide 202-327-6 94-36-0 Org. Perox. B H411 617-008-00-0 dibenzoyl peroxide; benzoyl peroxide 202-327-6 94-36-0 Org. Perox. B Eye Irrit. 2 Skin Sens. 1 H241 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H241 H319 H317 GHS01 H317 H400 H410 GHS01 GHS02 GHS07 GHS09 Dgr H241 H319 H317 617-010-00-1 1-hydroperoxycyclohexyl 1-hydroxycyclohexyl peroxide; [1] H317 H410 M = 10 M = 10 617-010-00-1 1-hydroperoxycyclohexyl 1-hydroxycyclohexyl peroxide; [1] 1,1’-dioxybiscyclohexan-1-ol; [2] cyclohexylidene hydroperoxide; [3] cyclohexanone, peroxide [4] 201-091-1 [1] … 139 unchanged lines … H314 H317 H411 617-023-00-2 tert-butyl hydroperoxide 200-915-7 75-91-2 Muta. 2 H341 GHS08 Wng H341 647-001-00-8 glucosidase, β- 232-589-7 9001-22-3 Resp. Sens. 1 H334 GHS08 Wng H341 617-024-00-8 tert-butyl 2-ethylperoxyhexanoate 221-110-7 3006-82-4 Repr. 1B Skin Sens. 1 H360FD H317 GHS08 GHS07 Dgr H360FD H317 647-001-00-8 glucosidase, β- 232-589-7 9001-22-3 Resp. Sens. 1 H334 GHS08 Dgr H334 647-002-00-3 cellulase 232-734-4 9012-54-8 Resp. Sens. 1 H334 GHS08 Dgr H334 647-003-00-9 cellobiohydrolase, exo- 253-465-9 37329-65-0 Resp. Sens. 1 H334 GHS08 Dgr H334 647-004-00-4 cellulases with the exception of those specified elsewhere in this Annex — — Resp. Sens. 1 H334 GHS08 … 24,737 unchanged lines … S: 61 650-055-00-5 silver sodium zirconium hydrogenphosphate 422-570-3 155925-27-2 N; R50-53 N R: 50/53 S: 60-61

in force 2025-09-01 MODIFIED

Amended by Regulation (EU) 2024/197 32024R0197

applies from: unchanged

Sources disagree — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. All are shown; none is overruled.

No explanation shipped — the difference between the two versions lies beyond the characters this stage can show, so no explanation was requested.

text before / after, on the event page →

in force 2025-02-01 MODIFIED

Amended by Regulation (EU) 2023/1435 32023R1435

applies from: unchanged

Sources disagree — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. All are shown; none is overruled.

Several boron entries in Table 3 (boric acid, diboron trioxide, tetraboron disodium heptaoxide hydrate and related salts) now carry a Note 11 reference in the Notes column, which was absent for these entries before.

The entry for tetraboron disodium heptaoxide hydrate and its related salts also gained an added semicolon separating the listed salt names.

The remainder of the text supplied is truncated, so no further differences beyond these can be described.

Cited: Annex VI, v1 · Annex VI, v2

text before / after, on the event page →

in force 2024-12-10 MODIFIED

Amended by Regulation (EU) 2024/2865 32024R2865

applies from: unchanged

Sources disagree — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. All are shown; none is overruled.

Section 2 now adds a new dossier component requiring a scientific justification where a harmonised classification and labelling proposal is made for a group of substances, alongside the existing proposal and justification elements.

The justification-for-other-effects paragraph in section 2 now lists additional excluded hazard categories, naming endocrine disruption for human health and the environment, persistent, bioaccumulative and toxic, very persistent and very bioaccumulative, persistent, mobile and toxic, and very persistent and very mobile, alongside the previously named carcinogenicity, mutagenicity, reprotoxicity and respiratory sensitisation.

That paragraph also now refers to the Union level rather than Community level and cites the active-substance exclusion by reference to Regulation (EU) No 1107/2009 and Regulation (EU) No 528/2012 instead of Directive 91/414/EEC and Directive 98/8/EC, while section 3's Table 3 entries shown in both texts are truncated before any further differences can be identified.

Cited: Annex VI, v2 · Annex VI, v1

text before / after, on the event page →

in force 2023-12-01 MODIFIED

Amended by Regulation (EU) 2022/692 32022R0692

applies from: unchanged

Sources disagree — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. All are shown; none is overruled.

No explanation shipped — the difference between the two versions lies beyond the characters this stage can show, so no explanation was requested.

text before / after, on the event page →

in force 2023-07-31 MODIFIED

Amended by Regulation (EU) 2023/1434 32023R1434

applies from: unchanged

Sources disagree — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. All are shown; none is overruled.

A new Note X has been added to the list of notes relating to the identification, classification and labelling of substances in section 1.1.3.1, describing classification based only on the properties of the part of the substance common to all substances in the entry, with the non-common part requiring separate evaluation for possibly more severe or broader classification.

Two new notes, Note 11 and Note 12, have been added to the list of notes relating to the classification and labelling of mixtures in section 1.1.3.2, both addressing when a mixture must be classified as a reproductive toxicant based on summed concentrations of relevant substances.

The corresponding before text in section 1.1.3.1 ends with Note W and the before text in section 1.1.3.2 ends with Note 10, without these additional notes present.

Cited: Annex VI, v2 · Annex VI, v1

text before / after, on the event page →

in force 2023-04-20 MODIFIED

Amended by Regulation (EU) 2023/707 32023R0707

applies from: unchanged

Sources disagree — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. All are shown; none is overruled.

The table of hazard class and category codes in section 1.1.2.1.1 now includes new rows for endocrine disruptor codes for human health (ED HH 1 and ED HH 2) and for the environment (ED ENV 1 and ED ENV 2), and it adds persistence-related codes PBT, vPvB, PMT and vPvM alongside the aspiration and aquatic hazard entries.

The corresponding earlier version of this table in the before text lists only the aspiration hazard and hazardous-to-the-aquatic-environment rows followed directly by the ozone layer row, without any endocrine disruptor or persistence/mobility codes.

Both texts are shown truncated partway through the substance listing table, so any further differences beyond this added set of hazard codes cannot be described here.

Cited: Annex VI, v2 · Annex VI, v1

text before / after, on the event page →

in force 2022-12-17 MODIFIED

Amended by Regulation (EU) 2021/849 32021R0849

applies from: unchanged

Sources disagree — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. All are shown; none is overruled.

In the visible portion of Section 3's table, several boron entries have been altered: the boric acid entry (005-007-00-2) and the diboron trioxide entry (005-008-00-8) drop the specific-concentration-limit notes and percentage thresholds for Repr. 1B / H360FD that appeared in the earlier text.

Entry 005-011-00-4, previously listed as disodium tetraborate anhydrous with two separate related entries for the decahydrate and pentahydrate forms (005-011-01-1 and 005-011-02-9), is replaced by a single consolidated entry combining tetraboron disodium heptaoxide hydrate, disodium tetraborate anhydrous, orthoboric acid sodium salt, disodium tetraborate decahydrate and disodium tetraborate pentahydrate as five components with corresponding EC and CAS numbers, without the earlier percentage-based concentration limit notes.

Because the provided texts are truncated partway through the table, only these changes within the shown fragment of Section 3 can be described, and any further differences elsewhere in the section cannot be determined from what was given.

Cited: Annex VI, v1 · Annex VI, v2

text before / after, on the event page →

in force 2022-03-01 MODIFIED

Amended by Regulation (EU) 2020/1182 32020R1182

applies from: unchanged

Sources disagree — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. All are shown; none is overruled.

No explanation shipped — the difference between the two versions lies beyond the characters this stage can show, so no explanation was requested.

text before / after, on the event page →

in force 2021-10-01 MODIFIED

Amended by Regulation (EU) 2021/797 32021R0797 · Regulation (EU) 2020/217 32020R0217 · Regulation (EU) 2021/1962 32021R1962

applies from: unchanged

The list of notes on identification, classification and labelling of substances gains two new entries, Note V and Note W, which were not present before.

Note V addresses evaluation of the substance when placed on the market as fibres or particles meeting certain criteria, including consideration of a higher category or additional routes of exposure, while Note W describes a carcinogenic hazard arising from inhalation of respirable dust and states that it does not constitute a classification criterion.

The notes relating to classification and labelling of mixtures also gain a new Note 10 concerning classification as a carcinogen by inhalation for powder mixtures containing titanium dioxide, and the truncated Table 3 material prevents further comparison of section 3 beyond what is shown.

Cited: Annex VI, v2 · Annex VI, v1

text before / after, on the event page →

in force 2021-05-10 MODIFIED

Amended by Regulation (EU) 2021/643 32021R0643

applies from: unknown (the text changed beyond its dates, so no date that moved can be read as the application date)

dates added to the text: 2008-05-30

Sources disagree — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. All are shown; none is overruled.

The wording of Notes J, K, L, M, N, P, Q and R in section 1.1.3.1 was rephrased from describing classification exemptions that 'need not apply' below stated thresholds to describing the harmonised classification as applying unless the substance is shown to fall below the stated threshold, with classification under Title II to be performed for those hazard classes in that case.

Note R was also expanded to add a cross-reference to Test method A.22 in the Annex to Commission Regulation (EC) No 440/2008, which was not present before.

In section 1.1.3.2, Notes 8 and 9 were changed from stating that the carcinogen or mutagen classification 'need not apply' below the stated formaldehyde concentration to stating that the classification 'shall apply' unless that concentration threshold is shown to be met.

Cited: Annex VI, v1 · Annex VI, v2

text before / after, on the event page →

in force 2020-10-17 MODIFIED

Amended by Regulation (EU) 2019/521 32019R0521

applies from: unchanged

Sources disagree — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. All are shown; none is overruled.

In Table 1.1 the row for flammable gases now lists the codes Flam. Gas 1A, Flam. Gas 1B, Flam. Gas 2 and Pyr. Gas in place of the earlier Flam. Gas 1 and Flam. Gas 2 codes.

Table 1.1 also gains a new row for desensitised explosives, listing the codes Desen. Expl. 1, Desen. Expl. 2, Desen. Expl. 3 and Desen. Expl. 4, which did not appear in the earlier text.

The text shown is truncated before the rest of the entries in Table 3, so any further differences beyond section 1.1.2.1.1 cannot be described.

Cited: Annex VI, v1 · Annex VI, v2

text before / after, on the event page →

in force 2020-05-01 MODIFIED

Amended by Regulation (EU) 2018/1480 32018R1480

applies from: unchanged

Sources disagree — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. All are shown; none is overruled.

The explanatory note above the Table 3 column headers was changed from a statement about a converted acute toxicity point estimate referencing Annex I Table 3.1.2 to a statement explaining that ATEs for oral and dermal exposure routes are expressed in mg/kg bodyweight.

The table column heading was also altered, splitting the earlier single heading covering specific concentration limits, M-factors and Acute Toxicity Estimates into a heading for specific concentration limits, M-factors and ATEs together with a separate Notes heading.

The remainder of the visible text, including the substance entries themselves, is unchanged between the two versions, and both texts are truncated before any further differences could be observed.

Cited: Annex VI, v1 · Annex VI, v2

text before / after, on the event page →

in force 2020-01-01 MODIFIED

Amended by Regulation (EU) 2020/11 32020R0011 · Regulation (EU) 2017/542 32017R0542

applies from: unchanged

Sources disagree — the text comparison found this change; the EU's own amendment metadata does not list it. Both are shown; neither is overruled.

No explanation shipped — the difference between the two versions lies beyond the characters this stage can show, so no explanation was requested.

text before / after, on the event page →

in force 2019-12-01 MODIFIED

Amended by Regulation (EU) 2018/669 32018R0669 · Regulation (EU) 2018/1480 32018R1480 · Regulation (EU) 2020/217 32020R0217

applies from: unchanged

The heading of section 1.1.1.4 was renamed from 'International Chemical Identification' to 'Chemical name', though the body text of that section remains the same.

In the Table 3 header, the column previously labelled 'International Chemical Identification' is now labelled 'Chemical name', and the column previously labelled 'Specific Conc. Limits, M-factors and ATE' is now labelled 'Specific Conc. Limits, M-factors', dropping the reference to Acute Toxicity Estimates (ATE).

The visible portion of the entries table otherwise continues with the same substances and codes, and both versions are truncated before any further differences can be observed.

Cited: Annex VI, v1 · Annex VI, v2

text before / after, on the event page →

in force 2018-12-01 MODIFIED

Amended by Regulation (EU) 2017/776 32017R0776

applies from: unchanged

Sources disagree — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. All are shown; none is overruled.

The reference in Note K to the substance identifier changed from "EINECS No" to "Einecs No", and the accompanying sentence dropped the parenthetical "(Table 3.2)" after the precautionary statement codes.

Note P similarly changed "EINECS No" to "Einecs No" and removed the "(Table 3.1)" and "or the S-phrases (2-)23-24-62 (Table 3.2)" wording, leaving only the precautionary statement codes as applying.

Note S and Note U were consolidated so that they now refer to a single "Table 3" instead of separately to Table 3.1 and Table 3.2, and the Part 3 table itself was retitled from "Table 3.1" to "Table 3", with the column heading changed from "Specific Conc. Limits, M-factors" to "Specific Conc. Limits, M-factors and ATE" and a new note on converted acute toxicity point estimates added before the table.

Cited: Annex VI, v1 · Annex VI, v2

text before / after, on the event page →

detected 2026-08-13 MODIFIED

no amending act named

applies from: unchanged

In the Hazard Class and Category Code table, a new entry "Skin Corr. 1" has been added ahead of the existing "Skin Corr. 1A" line under skin corrosion/irritation.

Note U has been expanded to list the specific codes Press. Gas (Comp.), Press. Gas (Liq.), Press. Gas (Ref. Liq.) and Press. Gas (Diss.), and to add a statement that aerosols are not to be classified as gases under pressure, with a cross-reference to Annex I, Part 2, Section 2.3.2.1, Note 2.

The text of Part 3 in both versions is cut off before the comparison could be completed, so only the changes visible within the shown portion, and not any further differences that may exist later in Part 3, can be described here.

Cited: Annex VI, v2 · Annex VI, v1

text before / after, on the event page →

in force 2017-06-01 MODIFIED

Amended by Regulation (EU) 2017/776 32017R0776

applies from: unchanged

Sources disagree — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. All are shown; none is overruled.

The introductory text in section 1 now refers throughout to a single 'Table 3' rather than to separate Tables 3.1 and 3.2, and references to Union level replace earlier references to Community level in the description of Parts 2 and 3.

Section 1.1.2.3 is retitled to add Acute Toxicity Estimates alongside specific concentration limits and M-factors, and its text now describes harmonised ATEs being listed in the same column of Table 3, including a rule on using the additivity formula in section 3.1.3.6 of Annex I and on establishing a value when a harmonised ATE is missing.

Section 1.1.3.2 gains two new notes, Note 8 and Note 9, addressing releasable formaldehyde concentrations for carcinogen and mutagen classification respectively, and section 1.2 and its subsections 1.2.1 through 1.2.4 are revised to refer to 'Table 3' instead of 'Table 3.1' and to drop the cross-reference to Directive 1999/45/EC generic concentrations in Note 1.

Cited: Annex VI, v2 · Annex VI, v1

text before / after, on the event page →

in force 2016-07-04 MODIFIED

Amended by Regulation (EU) 2016/918 32016R0918 · Regulation (EU) 2016/1179 32016R1179

applies from: unchanged

No explanation shipped — the difference between the two versions lies beyond the characters this stage can show, so no explanation was requested.

text before / after, on the event page →

detected 2026-08-13 MODIFIED

no amending act named

applies from: unchanged

No explanation shipped — the difference between the two versions lies beyond the characters this stage can show, so no explanation was requested.

text before / after, on the event page →

in force 2015-08-14 MODIFIED

Amended by Regulation (EU) 2015/1221 32015R1221

applies from: unknown

Sources disagree — the EU's own amendment metadata found this change; the text comparison finds no difference in the provision's text and the amending act's instructions do not mention it. All are shown; none is overruled.

No explanation shipped — the structural diff did not see this change, so it carries no text; another signal named the unit and the disagreement ships as `disputed`.

text before / after, on the event page →

in force 2015-06-01 MODIFIED

Amended by Regulation (EU) No 1297/2014 32014R1297 · Regulation (EU) No 605/2014 32014R0605

applies from: unchanged

Table 1.1 now includes additional hazard class and category codes for chemically unstable gases and replaces the flammable aerosol categories with a differently named aerosol category set spanning three categories instead of two.

The explanatory text on hazard statement codes now describes the added letters as differentiating the 3-digit hazard statement code, rather than simply being added to it.

Section 1.2.3 now describes H360 and H361 as covering effects on fertility and/or development rather than both, and replaces the earlier explanation of when the general statement may be replaced with wording referring to section 1.1.2.1.2 and to the obligations in Article 4(3) where a differentiation is not mentioned.

Cited: Annex VI, v2 · Annex VI, v1

text before / after, on the event page →

detected 2026-08-13 MODIFIED

no amending act named

applies from: unchanged

Both versions list the same substances under entry 006-004-00-9 (calcium carbide), but the AFTER text adds a Note reference of 'T' in the Notes column that is absent in the BEFORE text.

The AFTER text continues with an additional entry, 006-005-00-4 (thiram), that does not appear in the visible portion of the BEFORE text.

Both excerpts are truncated before the full extent of section 3's table entries can be compared, so no further differences beyond these visible changes can be described.

Cited: Annex VI, v1 · Annex VI, v2

text before / after, on the event page →

in force 2013-06-21 MODIFIED

Amended by Regulation (EU) No 487/2013 32013R0487 · Regulation (EU) No 517/2013 32013R0517 · Regulation (EU) No 944/2013 32013R0944 · Regulation (EU) No 618/2012 32012R0618 · Regulation (EU) No 758/2013 32013R0758

applies from: unchanged

In entry 005-007-00-2, the description of the second boric acid substance was simplified from a longer descriptive phrase naming crude natural boric acid with a purity limit to simply repeating the name boric acid.

Several entries for sodium perborate and sodium peroxoborate substances (005-017-00-7, 005-017-01-4, 005-019-00-8, 005-019-01-5) had their oxidising solid classification code changed from the abbreviation Oxid. Sol. to Ox. Sol.

The text shown is truncated before the end of the section, so only these visible formatting and abbreviation differences in Table 3.1 entries can be described.

Cited: Annex VI, v1 · Annex VI, v2

text before / after, on the event page →

in force 2011-04-19 MODIFIED

Amended by Regulation (EU) No 286/2011 32011R0286

applies from: unchanged

Sources disagree — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. All are shown; none is overruled.

In Table 1.1, the codes for respiratory and skin sensitisation were changed from single codes (Resp. Sens. 1 and Skin Sens. 1) to lists including sub-categories 1A and 1B, and the ozone-layer hazard code was changed from a bare 'Ozone' to 'Ozone 1'.

Section 1.1.2.3 rewrote the passage on M-factors, adding provisions for cases where separate M-factors exist for Aquatic Acute 1 and Aquatic Chronic 1 and for cases where a single M-factor covers both classifications, and removing the earlier sentence referring to an M-factor being used when a mixture is classified by the summation method.

Part 3's introductory text no longer states that Table 3.1 and Table 3.2 are listed in separate Volumes IIIa and IIIb, instead simply naming the tables.

Cited: Annex VI, v1 · Annex VI, v2

text before / after, on the event page →

in force 2010-12-01 MODIFIED

Amended by Regulation (EC) No 790/2009 32009R0790

applies from: unchanged

Sources disagree — the text comparison found this change; the EU's own amendment metadata does not list it and the amending act's instructions do not mention it. All are shown; none is overruled.

The Table 3.1 entries in Part 3 were revised to add several new substance listings, such as isobutyllithium, and to change classification, hazard statement, pictogram and concentration-limit entries for existing substances including aluminium lithium hydride and dibutyltin hydrogen borate.

Section 1.1.4.4 was altered only by removing a symbol reference in the description of entries not conforming between Table 3.1 and Table 3.2 for physical hazards, with the surrounding wording otherwise unchanged.

The text shown is truncated before the end of Table 3.1 in both versions, so further differences within Part 3 beyond the point shown cannot be described.

Cited: Annex VI, v2 · Annex VI, v1

text before / after, on the event page →